Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.

ABSTRACT:

Background

The paradigm of molecular negative hyperselection, beyond RAS and BRAF, identifies metastatic colorectal cancer (mCRC) patients with the greatest benefit from anti-epidermal growth factor receptor (anti-EGFR) agents. We hypothesize that applying this model to stage III colon cancer (CC) might identify a subgroup deriving benefit from anti-EGFRs in the adjuvant setting.

Patients and methods

We used a 'simplified PRESSING panel' grouping genomic alterations related to anti-EGFR primary resistance in mCRC, to select the proficient mismatch repair or microsatellite stable (pMMR/MSS) population of the randomized phase III PETACC-8 clinical trial, testing adjuvant FOLFOX ± cetuximab in resectable stage III CC. Patients without any tumor alterations in RAS/BRAF, or the s

SUBMITTER: Ambrosini M 

PROVIDER: S-EPMC12607000 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature